nodes	percent_of_prediction	percent_of_DWPC	metapath
Tadalafil—CYP3A4—Bexarotene—hematologic cancer	0.0421	0.0829	CbGbCtD
Tadalafil—CYP3A4—Busulfan—hematologic cancer	0.0392	0.0771	CbGbCtD
Tadalafil—CYP3A4—Lomustine—hematologic cancer	0.0392	0.0771	CbGbCtD
Tadalafil—CYP3A4—Thiotepa—hematologic cancer	0.0349	0.0687	CbGbCtD
Tadalafil—CYP3A4—Methoxsalen—hematologic cancer	0.0271	0.0534	CbGbCtD
Tadalafil—CYP3A4—Bortezomib—hematologic cancer	0.0258	0.0508	CbGbCtD
Tadalafil—CYP3A4—Daunorubicin—hematologic cancer	0.0247	0.0486	CbGbCtD
Tadalafil—CYP3A4—Cytarabine—hematologic cancer	0.0218	0.0429	CbGbCtD
Tadalafil—CYP3A4—Teniposide—hematologic cancer	0.0215	0.0422	CbGbCtD
Tadalafil—CYP3A4—Ifosfamide—hematologic cancer	0.0198	0.039	CbGbCtD
Tadalafil—CYP3A4—Imatinib—hematologic cancer	0.0189	0.0372	CbGbCtD
Tadalafil—CYP3A4—Ruxolitinib—hematologic cancer	0.0178	0.0351	CbGbCtD
Tadalafil—CYP3A4—Nilotinib—hematologic cancer	0.0172	0.0338	CbGbCtD
Tadalafil—CYP3A4—Vinorelbine—hematologic cancer	0.017	0.0335	CbGbCtD
Tadalafil—CYP3A4—Triamcinolone—hematologic cancer	0.0156	0.0307	CbGbCtD
Tadalafil—CYP3A4—Dasatinib—hematologic cancer	0.0152	0.0299	CbGbCtD
Tadalafil—CYP3A4—Mitoxantrone—hematologic cancer	0.015	0.0295	CbGbCtD
Tadalafil—CYP3A4—Betamethasone—hematologic cancer	0.0134	0.0263	CbGbCtD
Tadalafil—CYP3A4—Prednisolone—hematologic cancer	0.0132	0.026	CbGbCtD
Tadalafil—CYP3A4—Prednisone—hematologic cancer	0.0125	0.0245	CbGbCtD
Tadalafil—CYP3A4—Irinotecan—hematologic cancer	0.0118	0.0232	CbGbCtD
Tadalafil—CYP3A4—Vinblastine—hematologic cancer	0.0105	0.0207	CbGbCtD
Tadalafil—CYP3A4—Vincristine—hematologic cancer	0.0103	0.0203	CbGbCtD
Tadalafil—CYP3A4—Etoposide—hematologic cancer	0.00947	0.0186	CbGbCtD
Tadalafil—CYP3A4—Dexamethasone—hematologic cancer	0.00778	0.0153	CbGbCtD
Tadalafil—CYP3A4—Doxorubicin—hematologic cancer	0.00646	0.0127	CbGbCtD
Tadalafil—PDE11A—testis—hematologic cancer	0.00339	0.244	CbGeAlD
Tadalafil—PDE5A—hematopoietic system—hematologic cancer	0.00236	0.169	CbGeAlD
Tadalafil—PDE5A—gonad—hematologic cancer	0.00179	0.129	CbGeAlD
Tadalafil—PDE5A—blood—hematologic cancer	0.00156	0.112	CbGeAlD
Tadalafil—PDE5A—lung—hematologic cancer	0.00137	0.0983	CbGeAlD
Tadalafil—PDE5A—testis—hematologic cancer	0.00129	0.0928	CbGeAlD
Tadalafil—PDE5A—lymph node—hematologic cancer	0.000936	0.0672	CbGeAlD
Tadalafil—CYP3A4—hematopoietic system—hematologic cancer	0.000734	0.0528	CbGeAlD
Tadalafil—CYP3A4—blood—hematologic cancer	0.000487	0.035	CbGeAlD
Tadalafil—PDE5A—Hemostasis—FN1—hematologic cancer	0.000118	0.0015	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—CREBBP—hematologic cancer	0.000117	0.00149	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TRIO—hematologic cancer	0.000117	0.00149	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TRH—hematologic cancer	0.000117	0.00149	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CMA1—hematologic cancer	0.000117	0.00149	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AGO2—hematologic cancer	0.000114	0.00146	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SPHK1—hematologic cancer	0.000114	0.00146	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LPAR1—hematologic cancer	0.000113	0.00144	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HDAC9—hematologic cancer	0.000113	0.00144	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3CG—hematologic cancer	0.000112	0.00144	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—H3F3B—hematologic cancer	0.000112	0.00143	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CD—hematologic cancer	0.000111	0.00142	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PTPN11—hematologic cancer	0.000111	0.00141	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—ALB—hematologic cancer	0.00011	0.0014	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—GRB2—hematologic cancer	0.000108	0.00138	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—CSF2—hematologic cancer	0.000106	0.00136	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—SLC35B2—hematologic cancer	0.000106	0.00135	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3R1—hematologic cancer	0.000105	0.00134	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—EPHX1—hematologic cancer	0.000104	0.00133	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—CREBBP—hematologic cancer	0.000104	0.00133	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CNR2—hematologic cancer	0.000104	0.00133	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PDE4B—hematologic cancer	0.000104	0.00133	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FGF19—hematologic cancer	0.000103	0.00132	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—JAK1—hematologic cancer	0.000103	0.00131	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PRKCG—hematologic cancer	0.000103	0.00131	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RAC2—hematologic cancer	0.000102	0.00131	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—JAK2—hematologic cancer	0.000102	0.0013	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—DKK1—hematologic cancer	0.000101	0.00129	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—STAT5B—hematologic cancer	0.000101	0.00128	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3CD—hematologic cancer	9.89e-05	0.00126	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ADCY7—hematologic cancer	9.78e-05	0.00125	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—ALB—hematologic cancer	9.76e-05	0.00125	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CB—hematologic cancer	9.67e-05	0.00123	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—CSF2—hematologic cancer	9.64e-05	0.00123	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—IL2RA—hematologic cancer	9.57e-05	0.00122	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—XIAP—hematologic cancer	9.51e-05	0.00121	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3R1—hematologic cancer	9.34e-05	0.00119	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—JAK1—hematologic cancer	9.31e-05	0.00119	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PRKCG—hematologic cancer	9.31e-05	0.00119	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SH2B3—hematologic cancer	9.27e-05	0.00118	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SMARCA4—hematologic cancer	9.27e-05	0.00118	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GZMB—hematologic cancer	9.21e-05	0.00118	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—JAK2—hematologic cancer	9.07e-05	0.00116	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CTNNA1—hematologic cancer	8.99e-05	0.00115	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—EIF4EBP1—hematologic cancer	8.94e-05	0.00114	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CCL3—hematologic cancer	8.94e-05	0.00114	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HSPB1—hematologic cancer	8.94e-05	0.00114	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—IL2—hematologic cancer	8.88e-05	0.00113	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTHLH—hematologic cancer	8.84e-05	0.00113	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SDC1—hematologic cancer	8.84e-05	0.00113	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—IL2RA—hematologic cancer	8.69e-05	0.00111	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3CB—hematologic cancer	8.62e-05	0.0011	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTGER4—hematologic cancer	8.61e-05	0.0011	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—LCK—hematologic cancer	8.56e-05	0.00109	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—H3F3A—hematologic cancer	8.39e-05	0.00107	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PRKCZ—hematologic cancer	8.16e-05	0.00104	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CG—hematologic cancer	7.97e-05	0.00102	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—EP300—hematologic cancer	7.97e-05	0.00102	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—IL2—hematologic cancer	7.91e-05	0.00101	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PARP1—hematologic cancer	7.88e-05	0.00101	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FBXW7—hematologic cancer	7.75e-05	0.000989	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—SRC—hematologic cancer	7.75e-05	0.000989	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HDAC2—hematologic cancer	7.6e-05	0.00097	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CXCR4—hematologic cancer	7.6e-05	0.00097	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—VEGFA—hematologic cancer	7.55e-05	0.000963	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—NRAS—hematologic cancer	7.45e-05	0.000951	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CBL—hematologic cancer	7.41e-05	0.000945	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL3—hematologic cancer	7.33e-05	0.000935	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CG—hematologic cancer	7.24e-05	0.000924	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTPN1—hematologic cancer	7.21e-05	0.00092	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—MAPK3—hematologic cancer	7.14e-05	0.000911	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PTPN11—hematologic cancer	7.11e-05	0.000908	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—EP300—hematologic cancer	7.1e-05	0.000906	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RASGRP1—hematologic cancer	7.09e-05	0.000905	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HSP90AA1—hematologic cancer	7.07e-05	0.000902	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SYK—hematologic cancer	7.07e-05	0.000902	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CD—hematologic cancer	7.01e-05	0.000895	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—TGFB1—hematologic cancer	6.93e-05	0.000884	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—SRC—hematologic cancer	6.91e-05	0.000881	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—CREB1—hematologic cancer	6.89e-05	0.00088	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	6.82e-05	0.00087	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—STAT1—hematologic cancer	6.82e-05	0.00087	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—CCL2—hematologic cancer	6.74e-05	0.000861	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	6.73e-05	0.000859	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—VEGFA—hematologic cancer	6.73e-05	0.000858	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—IL6R—hematologic cancer	6.72e-05	0.000858	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—NRAS—hematologic cancer	6.64e-05	0.000848	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3R1—hematologic cancer	6.62e-05	0.000845	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—JAK2—hematologic cancer	6.43e-05	0.000821	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—KRAS—hematologic cancer	6.42e-05	0.000819	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	6.41e-05	0.000818	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—MAP2K1—hematologic cancer	6.41e-05	0.000818	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—GRB2—hematologic cancer	6.38e-05	0.000814	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CD—hematologic cancer	6.37e-05	0.000812	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—MAPK3—hematologic cancer	6.36e-05	0.000812	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PDGFA—hematologic cancer	6.36e-05	0.000812	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	6.33e-05	0.000807	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—KITLG—hematologic cancer	6.27e-05	0.0008	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—TGFB1—hematologic cancer	6.17e-05	0.000788	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—STAT5A—hematologic cancer	6.13e-05	0.000782	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CB—hematologic cancer	6.11e-05	0.00078	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CDKN2B—hematologic cancer	6.07e-05	0.000775	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3R1—hematologic cancer	6.01e-05	0.000767	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CA—hematologic cancer	5.89e-05	0.000752	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CD86—hematologic cancer	5.88e-05	0.00075	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—JAK2—hematologic cancer	5.84e-05	0.000746	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HES1—hematologic cancer	5.79e-05	0.000739	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NCOR1—hematologic cancer	5.76e-05	0.000735	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—KRAS—hematologic cancer	5.72e-05	0.00073	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—TP53—hematologic cancer	5.7e-05	0.000728	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FGF1—hematologic cancer	5.7e-05	0.000727	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CSF2—hematologic cancer	5.7e-05	0.000727	CbGpPWpGaD
Tadalafil—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	5.66e-05	0.000722	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FOXO1—hematologic cancer	5.61e-05	0.000716	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—IL2—hematologic cancer	5.61e-05	0.000716	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PDGFRB—hematologic cancer	5.6e-05	0.000715	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—MTR—hematologic cancer	5.56e-05	0.00071	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CB—hematologic cancer	5.55e-05	0.000708	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PDGFRA—hematologic cancer	5.52e-05	0.000704	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—JAK1—hematologic cancer	5.5e-05	0.000702	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PRKCG—hematologic cancer	5.5e-05	0.000702	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—HRAS—hematologic cancer	5.45e-05	0.000696	CbGpPWpGaD
Tadalafil—Eye disorder—Epirubicin—hematologic cancer	5.33e-05	0.000133	CcSEcCtD
Tadalafil—Hypersensitivity—Etoposide—hematologic cancer	5.32e-05	0.000133	CcSEcCtD
Tadalafil—Tinnitus—Epirubicin—hematologic cancer	5.32e-05	0.000133	CcSEcCtD
Tadalafil—Haemoglobin—Doxorubicin—hematologic cancer	5.3e-05	0.000133	CcSEcCtD
Tadalafil—Headache—Gemcitabine—hematologic cancer	5.3e-05	0.000133	CcSEcCtD
Tadalafil—Nausea—Vincristine—hematologic cancer	5.3e-05	0.000133	CcSEcCtD
Tadalafil—Flushing—Epirubicin—hematologic cancer	5.29e-05	0.000132	CcSEcCtD
Tadalafil—Cardiac disorder—Epirubicin—hematologic cancer	5.29e-05	0.000132	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	5.29e-05	0.000675	CbGpPWpGaD
Tadalafil—Rhinitis—Doxorubicin—hematologic cancer	5.29e-05	0.000132	CcSEcCtD
Tadalafil—Haemorrhage—Doxorubicin—hematologic cancer	5.28e-05	0.000132	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—PIK3CA—hematologic cancer	5.25e-05	0.00067	CbGpPWpGaD
Tadalafil—Hypersensitivity—Prednisolone—hematologic cancer	5.25e-05	0.000131	CcSEcCtD
Tadalafil—Hypoaesthesia—Doxorubicin—hematologic cancer	5.25e-05	0.000131	CcSEcCtD
Tadalafil—Pharyngitis—Doxorubicin—hematologic cancer	5.24e-05	0.000131	CcSEcCtD
Tadalafil—Dyspepsia—Dexamethasone—hematologic cancer	5.23e-05	0.000131	CcSEcCtD
Tadalafil—Dyspepsia—Betamethasone—hematologic cancer	5.23e-05	0.000131	CcSEcCtD
Tadalafil—Urinary tract disorder—Doxorubicin—hematologic cancer	5.21e-05	0.00013	CcSEcCtD
Tadalafil—Urticaria—Triamcinolone—hematologic cancer	5.21e-05	0.00013	CcSEcCtD
Tadalafil—Oedema peripheral—Doxorubicin—hematologic cancer	5.2e-05	0.00013	CcSEcCtD
Tadalafil—Asthenia—Etoposide—hematologic cancer	5.18e-05	0.00013	CcSEcCtD
Tadalafil—Connective tissue disorder—Doxorubicin—hematologic cancer	5.18e-05	0.00013	CcSEcCtD
Tadalafil—Oedema—Prednisone—hematologic cancer	5.18e-05	0.00013	CcSEcCtD
Tadalafil—Angiopathy—Epirubicin—hematologic cancer	5.17e-05	0.00013	CcSEcCtD
Tadalafil—Urethral disorder—Doxorubicin—hematologic cancer	5.17e-05	0.000129	CcSEcCtD
Tadalafil—Nausea—Irinotecan—hematologic cancer	5.16e-05	0.000129	CcSEcCtD
Tadalafil—Nausea—Mitoxantrone—hematologic cancer	5.16e-05	0.000129	CcSEcCtD
Tadalafil—Immune system disorder—Epirubicin—hematologic cancer	5.15e-05	0.000129	CcSEcCtD
Tadalafil—Infection—Prednisone—hematologic cancer	5.15e-05	0.000129	CcSEcCtD
Tadalafil—Mediastinal disorder—Epirubicin—hematologic cancer	5.14e-05	0.000129	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—IL2RA—hematologic cancer	5.14e-05	0.000655	CbGpPWpGaD
Tadalafil—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.13e-05	0.000129	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.13e-05	0.000129	CcSEcCtD
Tadalafil—Back pain—Methotrexate—hematologic cancer	5.13e-05	0.000128	CcSEcCtD
Tadalafil—Fatigue—Dexamethasone—hematologic cancer	5.13e-05	0.000128	CcSEcCtD
Tadalafil—Fatigue—Betamethasone—hematologic cancer	5.13e-05	0.000128	CcSEcCtD
Tadalafil—Pruritus—Etoposide—hematologic cancer	5.11e-05	0.000128	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—IL2—hematologic cancer	5.1e-05	0.00065	CbGpPWpGaD
Tadalafil—Shock—Prednisone—hematologic cancer	5.1e-05	0.000128	CcSEcCtD
Tadalafil—Pain—Dexamethasone—hematologic cancer	5.09e-05	0.000127	CcSEcCtD
Tadalafil—Pain—Betamethasone—hematologic cancer	5.09e-05	0.000127	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—TP53—hematologic cancer	5.08e-05	0.000649	CbGpPWpGaD
Tadalafil—Nervous system disorder—Prednisone—hematologic cancer	5.08e-05	0.000127	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—TERT—hematologic cancer	5.08e-05	0.000648	CbGpPWpGaD
Tadalafil—Tachycardia—Prednisone—hematologic cancer	5.05e-05	0.000127	CcSEcCtD
Tadalafil—Skin disorder—Prednisone—hematologic cancer	5.03e-05	0.000126	CcSEcCtD
Tadalafil—Nausea—Gemcitabine—hematologic cancer	5.03e-05	0.000126	CcSEcCtD
Tadalafil—Vomiting—Cisplatin—hematologic cancer	5.02e-05	0.000126	CcSEcCtD
Tadalafil—Hyperhidrosis—Prednisone—hematologic cancer	5.01e-05	0.000125	CcSEcCtD
Tadalafil—Vision blurred—Methotrexate—hematologic cancer	5e-05	0.000125	CcSEcCtD
Tadalafil—Mental disorder—Epirubicin—hematologic cancer	4.99e-05	0.000125	CcSEcCtD
Tadalafil—Erythema multiforme—Doxorubicin—hematologic cancer	4.99e-05	0.000125	CcSEcCtD
Tadalafil—Rash—Cisplatin—hematologic cancer	4.97e-05	0.000125	CcSEcCtD
Tadalafil—Dermatitis—Cisplatin—hematologic cancer	4.97e-05	0.000124	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PDGFB—hematologic cancer	4.96e-05	0.000632	CbGpPWpGaD
Tadalafil—Diarrhoea—Etoposide—hematologic cancer	4.94e-05	0.000124	CcSEcCtD
Tadalafil—Eye disorder—Doxorubicin—hematologic cancer	4.93e-05	0.000123	CcSEcCtD
Tadalafil—Tinnitus—Doxorubicin—hematologic cancer	4.92e-05	0.000123	CcSEcCtD
Tadalafil—Cardiac disorder—Doxorubicin—hematologic cancer	4.9e-05	0.000123	CcSEcCtD
Tadalafil—Flushing—Doxorubicin—hematologic cancer	4.9e-05	0.000123	CcSEcCtD
Tadalafil—Gastrointestinal pain—Betamethasone—hematologic cancer	4.86e-05	0.000122	CcSEcCtD
Tadalafil—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.86e-05	0.000122	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—HRAS—hematologic cancer	4.86e-05	0.00062	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TSC2—hematologic cancer	4.84e-05	0.000618	CbGpPWpGaD
Tadalafil—Hypersensitivity—Triamcinolone—hematologic cancer	4.83e-05	0.000121	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—AKT1—hematologic cancer	4.82e-05	0.000614	CbGpPWpGaD
Tadalafil—Back pain—Epirubicin—hematologic cancer	4.8e-05	0.00012	CcSEcCtD
Tadalafil—Angiopathy—Doxorubicin—hematologic cancer	4.79e-05	0.00012	CcSEcCtD
Tadalafil—Dizziness—Etoposide—hematologic cancer	4.78e-05	0.00012	CcSEcCtD
Tadalafil—Muscle spasms—Epirubicin—hematologic cancer	4.77e-05	0.000119	CcSEcCtD
Tadalafil—Immune system disorder—Doxorubicin—hematologic cancer	4.76e-05	0.000119	CcSEcCtD
Tadalafil—Vertigo—Methotrexate—hematologic cancer	4.76e-05	0.000119	CcSEcCtD
Tadalafil—Mediastinal disorder—Doxorubicin—hematologic cancer	4.75e-05	0.000119	CcSEcCtD
Tadalafil—Urticaria—Betamethasone—hematologic cancer	4.72e-05	0.000118	CcSEcCtD
Tadalafil—Urticaria—Dexamethasone—hematologic cancer	4.72e-05	0.000118	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.72e-05	0.000118	CcSEcCtD
Tadalafil—Dizziness—Prednisolone—hematologic cancer	4.71e-05	0.000118	CcSEcCtD
Tadalafil—Asthenia—Triamcinolone—hematologic cancer	4.7e-05	0.000118	CcSEcCtD
Tadalafil—Abdominal pain—Betamethasone—hematologic cancer	4.7e-05	0.000118	CcSEcCtD
Tadalafil—Abdominal pain—Dexamethasone—hematologic cancer	4.7e-05	0.000118	CcSEcCtD
Tadalafil—Nausea—Cisplatin—hematologic cancer	4.69e-05	0.000117	CcSEcCtD
Tadalafil—Insomnia—Prednisone—hematologic cancer	4.68e-05	0.000117	CcSEcCtD
Tadalafil—Vision blurred—Epirubicin—hematologic cancer	4.68e-05	0.000117	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—FGFR3—hematologic cancer	4.66e-05	0.000595	CbGpPWpGaD
Tadalafil—Paraesthesia—Prednisone—hematologic cancer	4.65e-05	0.000116	CcSEcCtD
Tadalafil—Pruritus—Triamcinolone—hematologic cancer	4.64e-05	0.000116	CcSEcCtD
Tadalafil—Cough—Methotrexate—hematologic cancer	4.63e-05	0.000116	CcSEcCtD
Tadalafil—Mental disorder—Doxorubicin—hematologic cancer	4.62e-05	0.000116	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—MAPK14—hematologic cancer	4.61e-05	0.000589	CbGpPWpGaD
Tadalafil—Convulsion—Methotrexate—hematologic cancer	4.6e-05	0.000115	CcSEcCtD
Tadalafil—Vomiting—Etoposide—hematologic cancer	4.59e-05	0.000115	CcSEcCtD
Tadalafil—Dyspepsia—Prednisone—hematologic cancer	4.56e-05	0.000114	CcSEcCtD
Tadalafil—Rash—Etoposide—hematologic cancer	4.56e-05	0.000114	CcSEcCtD
Tadalafil—Dermatitis—Etoposide—hematologic cancer	4.55e-05	0.000114	CcSEcCtD
Tadalafil—Headache—Etoposide—hematologic cancer	4.53e-05	0.000113	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—ESR1—hematologic cancer	4.53e-05	0.000577	CbGpPWpGaD
Tadalafil—Arthralgia—Methotrexate—hematologic cancer	4.52e-05	0.000113	CcSEcCtD
Tadalafil—Chest pain—Methotrexate—hematologic cancer	4.52e-05	0.000113	CcSEcCtD
Tadalafil—Myalgia—Methotrexate—hematologic cancer	4.52e-05	0.000113	CcSEcCtD
Tadalafil—Rash—Prednisolone—hematologic cancer	4.49e-05	0.000113	CcSEcCtD
Tadalafil—Dermatitis—Prednisolone—hematologic cancer	4.49e-05	0.000112	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.48e-05	0.000112	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—FN1—hematologic cancer	4.47e-05	0.00057	CbGpPWpGaD
Tadalafil—Fatigue—Prednisone—hematologic cancer	4.47e-05	0.000112	CcSEcCtD
Tadalafil—Headache—Prednisolone—hematologic cancer	4.46e-05	0.000112	CcSEcCtD
Tadalafil—Discomfort—Methotrexate—hematologic cancer	4.46e-05	0.000112	CcSEcCtD
Tadalafil—Vertigo—Epirubicin—hematologic cancer	4.46e-05	0.000112	CcSEcCtD
Tadalafil—Syncope—Epirubicin—hematologic cancer	4.45e-05	0.000111	CcSEcCtD
Tadalafil—Back pain—Doxorubicin—hematologic cancer	4.44e-05	0.000111	CcSEcCtD
Tadalafil—Constipation—Prednisone—hematologic cancer	4.43e-05	0.000111	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—NFKBIA—hematologic cancer	4.42e-05	0.000564	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—BAD—hematologic cancer	4.42e-05	0.000564	CbGpPWpGaD
Tadalafil—Muscle spasms—Doxorubicin—hematologic cancer	4.42e-05	0.000111	CcSEcCtD
Tadalafil—Palpitations—Epirubicin—hematologic cancer	4.39e-05	0.00011	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—NOTCH1—hematologic cancer	4.37e-05	0.000558	CbGpPWpGaD
Tadalafil—Loss of consciousness—Epirubicin—hematologic cancer	4.36e-05	0.000109	CcSEcCtD
Tadalafil—Dizziness—Triamcinolone—hematologic cancer	4.33e-05	0.000109	CcSEcCtD
Tadalafil—Cough—Epirubicin—hematologic cancer	4.33e-05	0.000108	CcSEcCtD
Tadalafil—Vision blurred—Doxorubicin—hematologic cancer	4.33e-05	0.000108	CcSEcCtD
Tadalafil—Convulsion—Epirubicin—hematologic cancer	4.3e-05	0.000108	CcSEcCtD
Tadalafil—Infection—Methotrexate—hematologic cancer	4.3e-05	0.000108	CcSEcCtD
Tadalafil—Nausea—Etoposide—hematologic cancer	4.29e-05	0.000107	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—AKT1—hematologic cancer	4.29e-05	0.000548	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CD80—hematologic cancer	4.29e-05	0.000547	CbGpPWpGaD
Tadalafil—Hypertension—Epirubicin—hematologic cancer	4.29e-05	0.000107	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—KIT—hematologic cancer	4.28e-05	0.000546	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CG—hematologic cancer	4.28e-05	0.000546	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—NRAS—hematologic cancer	4.28e-05	0.000546	CbGpPWpGaD
Tadalafil—Asthenia—Betamethasone—hematologic cancer	4.27e-05	0.000107	CcSEcCtD
Tadalafil—Asthenia—Dexamethasone—hematologic cancer	4.27e-05	0.000107	CcSEcCtD
Tadalafil—Nervous system disorder—Methotrexate—hematologic cancer	4.24e-05	0.000106	CcSEcCtD
Tadalafil—Gastrointestinal pain—Prednisone—hematologic cancer	4.24e-05	0.000106	CcSEcCtD
Tadalafil—Nausea—Prednisolone—hematologic cancer	4.23e-05	0.000106	CcSEcCtD
Tadalafil—Arthralgia—Epirubicin—hematologic cancer	4.23e-05	0.000106	CcSEcCtD
Tadalafil—Chest pain—Epirubicin—hematologic cancer	4.23e-05	0.000106	CcSEcCtD
Tadalafil—Myalgia—Epirubicin—hematologic cancer	4.23e-05	0.000106	CcSEcCtD
Tadalafil—Pruritus—Betamethasone—hematologic cancer	4.21e-05	0.000105	CcSEcCtD
Tadalafil—Pruritus—Dexamethasone—hematologic cancer	4.21e-05	0.000105	CcSEcCtD
Tadalafil—Skin disorder—Methotrexate—hematologic cancer	4.2e-05	0.000105	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PTPN11—hematologic cancer	4.2e-05	0.000536	CbGpPWpGaD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.2e-05	0.000105	CcSEcCtD
Tadalafil—Hyperhidrosis—Methotrexate—hematologic cancer	4.18e-05	0.000105	CcSEcCtD
Tadalafil—Discomfort—Epirubicin—hematologic cancer	4.17e-05	0.000105	CcSEcCtD
Tadalafil—Vomiting—Triamcinolone—hematologic cancer	4.17e-05	0.000104	CcSEcCtD
Tadalafil—Rash—Triamcinolone—hematologic cancer	4.13e-05	0.000103	CcSEcCtD
Tadalafil—Dry mouth—Epirubicin—hematologic cancer	4.13e-05	0.000103	CcSEcCtD
Tadalafil—Dermatitis—Triamcinolone—hematologic cancer	4.13e-05	0.000103	CcSEcCtD
Tadalafil—Vertigo—Doxorubicin—hematologic cancer	4.13e-05	0.000103	CcSEcCtD
Tadalafil—Syncope—Doxorubicin—hematologic cancer	4.12e-05	0.000103	CcSEcCtD
Tadalafil—Urticaria—Prednisone—hematologic cancer	4.11e-05	0.000103	CcSEcCtD
Tadalafil—Headache—Triamcinolone—hematologic cancer	4.11e-05	0.000103	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—MAPK3—hematologic cancer	4.1e-05	0.000523	CbGpPWpGaD
Tadalafil—Abdominal pain—Prednisone—hematologic cancer	4.09e-05	0.000103	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CREB1—hematologic cancer	4.07e-05	0.00052	CbGpPWpGaD
Tadalafil—Diarrhoea—Betamethasone—hematologic cancer	4.07e-05	0.000102	CcSEcCtD
Tadalafil—Diarrhoea—Dexamethasone—hematologic cancer	4.07e-05	0.000102	CcSEcCtD
Tadalafil—Palpitations—Doxorubicin—hematologic cancer	4.06e-05	0.000102	CcSEcCtD
Tadalafil—Oedema—Epirubicin—hematologic cancer	4.05e-05	0.000101	CcSEcCtD
Tadalafil—Hypotension—Methotrexate—hematologic cancer	4.04e-05	0.000101	CcSEcCtD
Tadalafil—Loss of consciousness—Doxorubicin—hematologic cancer	4.04e-05	0.000101	CcSEcCtD
Tadalafil—Infection—Epirubicin—hematologic cancer	4.02e-05	0.000101	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—BRAF—hematologic cancer	4.02e-05	0.000513	CbGpPWpGaD
Tadalafil—Cough—Doxorubicin—hematologic cancer	4.01e-05	0.0001	CcSEcCtD
Tadalafil—Shock—Epirubicin—hematologic cancer	3.99e-05	9.98e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CCL2—hematologic cancer	3.98e-05	0.000508	CbGpPWpGaD
Tadalafil—Convulsion—Doxorubicin—hematologic cancer	3.98e-05	9.96e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—IL6R—hematologic cancer	3.97e-05	0.000507	CbGpPWpGaD
Tadalafil—Nervous system disorder—Epirubicin—hematologic cancer	3.97e-05	9.95e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CREBBP—hematologic cancer	3.97e-05	0.000506	CbGpPWpGaD
Tadalafil—Hypertension—Doxorubicin—hematologic cancer	3.96e-05	9.93e-05	CcSEcCtD
Tadalafil—Tachycardia—Epirubicin—hematologic cancer	3.95e-05	9.9e-05	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.94e-05	9.87e-05	CcSEcCtD
Tadalafil—Skin disorder—Epirubicin—hematologic cancer	3.93e-05	9.85e-05	CcSEcCtD
Tadalafil—Dizziness—Dexamethasone—hematologic cancer	3.93e-05	9.85e-05	CcSEcCtD
Tadalafil—Dizziness—Betamethasone—hematologic cancer	3.93e-05	9.85e-05	CcSEcCtD
Tadalafil—Hyperhidrosis—Epirubicin—hematologic cancer	3.92e-05	9.8e-05	CcSEcCtD
Tadalafil—Insomnia—Methotrexate—hematologic cancer	3.91e-05	9.8e-05	CcSEcCtD
Tadalafil—Myalgia—Doxorubicin—hematologic cancer	3.91e-05	9.79e-05	CcSEcCtD
Tadalafil—Arthralgia—Doxorubicin—hematologic cancer	3.91e-05	9.79e-05	CcSEcCtD
Tadalafil—Chest pain—Doxorubicin—hematologic cancer	3.91e-05	9.79e-05	CcSEcCtD
Tadalafil—Nausea—Triamcinolone—hematologic cancer	3.89e-05	9.75e-05	CcSEcCtD
Tadalafil—Paraesthesia—Methotrexate—hematologic cancer	3.89e-05	9.73e-05	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.88e-05	9.72e-05	CcSEcCtD
Tadalafil—Discomfort—Doxorubicin—hematologic cancer	3.86e-05	9.67e-05	CcSEcCtD
Tadalafil—Dyspnoea—Methotrexate—hematologic cancer	3.86e-05	9.66e-05	CcSEcCtD
Tadalafil—Somnolence—Methotrexate—hematologic cancer	3.85e-05	9.63e-05	CcSEcCtD
Tadalafil—Dry mouth—Doxorubicin—hematologic cancer	3.82e-05	9.57e-05	CcSEcCtD
Tadalafil—Hypersensitivity—Prednisone—hematologic cancer	3.82e-05	9.55e-05	CcSEcCtD
Tadalafil—Dyspepsia—Methotrexate—hematologic cancer	3.81e-05	9.54e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—MAP2K1—hematologic cancer	3.79e-05	0.000483	CbGpPWpGaD
Tadalafil—Hypotension—Epirubicin—hematologic cancer	3.78e-05	9.48e-05	CcSEcCtD
Tadalafil—Vomiting—Betamethasone—hematologic cancer	3.78e-05	9.47e-05	CcSEcCtD
Tadalafil—Vomiting—Dexamethasone—hematologic cancer	3.78e-05	9.47e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PIK3CD—hematologic cancer	3.76e-05	0.00048	CbGpPWpGaD
Tadalafil—Rash—Betamethasone—hematologic cancer	3.75e-05	9.39e-05	CcSEcCtD
Tadalafil—Rash—Dexamethasone—hematologic cancer	3.75e-05	9.39e-05	CcSEcCtD
Tadalafil—Oedema—Doxorubicin—hematologic cancer	3.75e-05	9.38e-05	CcSEcCtD
Tadalafil—Dermatitis—Betamethasone—hematologic cancer	3.75e-05	9.38e-05	CcSEcCtD
Tadalafil—Dermatitis—Dexamethasone—hematologic cancer	3.75e-05	9.38e-05	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.74e-05	9.36e-05	CcSEcCtD
Tadalafil—Fatigue—Methotrexate—hematologic cancer	3.73e-05	9.34e-05	CcSEcCtD
Tadalafil—Headache—Dexamethasone—hematologic cancer	3.73e-05	9.33e-05	CcSEcCtD
Tadalafil—Headache—Betamethasone—hematologic cancer	3.73e-05	9.33e-05	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CA—hematologic cancer	3.73e-05	0.000475	CbGpPWpGaD
Tadalafil—Infection—Doxorubicin—hematologic cancer	3.72e-05	9.32e-05	CcSEcCtD
Tadalafil—Asthenia—Prednisone—hematologic cancer	3.72e-05	9.3e-05	CcSEcCtD
Tadalafil—Pain—Methotrexate—hematologic cancer	3.7e-05	9.27e-05	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.69e-05	9.24e-05	CcSEcCtD
Tadalafil—Shock—Doxorubicin—hematologic cancer	3.69e-05	9.23e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—KRAS—hematologic cancer	3.68e-05	0.00047	CbGpPWpGaD
Tadalafil—Nervous system disorder—Doxorubicin—hematologic cancer	3.68e-05	9.2e-05	CcSEcCtD
Tadalafil—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	3.67e-05	0.000468	CbGpPWpGaD
Tadalafil—Pruritus—Prednisone—hematologic cancer	3.66e-05	9.17e-05	CcSEcCtD
Tadalafil—Insomnia—Epirubicin—hematologic cancer	3.66e-05	9.17e-05	CcSEcCtD
Tadalafil—Tachycardia—Doxorubicin—hematologic cancer	3.66e-05	9.16e-05	CcSEcCtD
Tadalafil—Skin disorder—Doxorubicin—hematologic cancer	3.64e-05	9.11e-05	CcSEcCtD
Tadalafil—Paraesthesia—Epirubicin—hematologic cancer	3.64e-05	9.11e-05	CcSEcCtD
Tadalafil—Hyperhidrosis—Doxorubicin—hematologic cancer	3.62e-05	9.07e-05	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	3.62e-05	0.000461	CbGpPWpGaD
Tadalafil—Dyspnoea—Epirubicin—hematologic cancer	3.61e-05	9.04e-05	CcSEcCtD
Tadalafil—Somnolence—Epirubicin—hematologic cancer	3.6e-05	9.02e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—FGF2—hematologic cancer	3.6e-05	0.000459	CbGpPWpGaD
Tadalafil—Dyspepsia—Epirubicin—hematologic cancer	3.57e-05	8.93e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—PIK3R1—hematologic cancer	3.55e-05	0.000453	CbGpPWpGaD
Tadalafil—Diarrhoea—Prednisone—hematologic cancer	3.54e-05	8.87e-05	CcSEcCtD
Tadalafil—Gastrointestinal pain—Methotrexate—hematologic cancer	3.54e-05	8.86e-05	CcSEcCtD
Tadalafil—Nausea—Betamethasone—hematologic cancer	3.53e-05	8.84e-05	CcSEcCtD
Tadalafil—Nausea—Dexamethasone—hematologic cancer	3.53e-05	8.84e-05	CcSEcCtD
Tadalafil—Hypotension—Doxorubicin—hematologic cancer	3.5e-05	8.77e-05	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.5e-05	8.76e-05	CcSEcCtD
Tadalafil—Fatigue—Epirubicin—hematologic cancer	3.49e-05	8.74e-05	CcSEcCtD
Tadalafil—Constipation—Epirubicin—hematologic cancer	3.46e-05	8.67e-05	CcSEcCtD
Tadalafil—Pain—Epirubicin—hematologic cancer	3.46e-05	8.67e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—JAK2—hematologic cancer	3.45e-05	0.00044	CbGpPWpGaD
Tadalafil—Urticaria—Methotrexate—hematologic cancer	3.44e-05	8.61e-05	CcSEcCtD
Tadalafil—Dizziness—Prednisone—hematologic cancer	3.42e-05	8.57e-05	CcSEcCtD
Tadalafil—Abdominal pain—Methotrexate—hematologic cancer	3.42e-05	8.57e-05	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.41e-05	8.55e-05	CcSEcCtD
Tadalafil—Insomnia—Doxorubicin—hematologic cancer	3.39e-05	8.49e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CA—hematologic cancer	3.38e-05	0.000432	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	3.37e-05	0.00043	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MDM2—hematologic cancer	3.37e-05	0.00043	CbGpPWpGaD
Tadalafil—Paraesthesia—Doxorubicin—hematologic cancer	3.37e-05	8.43e-05	CcSEcCtD
Tadalafil—Dyspnoea—Doxorubicin—hematologic cancer	3.34e-05	8.37e-05	CcSEcCtD
Tadalafil—Somnolence—Doxorubicin—hematologic cancer	3.33e-05	8.34e-05	CcSEcCtD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	3.32e-05	0.000424	CbGpPWpGaD
Tadalafil—Gastrointestinal pain—Epirubicin—hematologic cancer	3.31e-05	8.29e-05	CcSEcCtD
Tadalafil—Dyspepsia—Doxorubicin—hematologic cancer	3.3e-05	8.26e-05	CcSEcCtD
Tadalafil—Vomiting—Prednisone—hematologic cancer	3.29e-05	8.24e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—MTOR—hematologic cancer	3.28e-05	0.000418	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CB—hematologic cancer	3.28e-05	0.000418	CbGpPWpGaD
Tadalafil—Rash—Prednisone—hematologic cancer	3.27e-05	8.18e-05	CcSEcCtD
Tadalafil—Dermatitis—Prednisone—hematologic cancer	3.26e-05	8.17e-05	CcSEcCtD
Tadalafil—Headache—Prednisone—hematologic cancer	3.24e-05	8.12e-05	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.24e-05	8.1e-05	CcSEcCtD
Tadalafil—Fatigue—Doxorubicin—hematologic cancer	3.23e-05	8.09e-05	CcSEcCtD
Tadalafil—Urticaria—Epirubicin—hematologic cancer	3.22e-05	8.06e-05	CcSEcCtD
Tadalafil—Constipation—Doxorubicin—hematologic cancer	3.21e-05	8.02e-05	CcSEcCtD
Tadalafil—Pain—Doxorubicin—hematologic cancer	3.21e-05	8.02e-05	CcSEcCtD
Tadalafil—Abdominal pain—Epirubicin—hematologic cancer	3.2e-05	8.02e-05	CcSEcCtD
Tadalafil—Hypersensitivity—Methotrexate—hematologic cancer	3.19e-05	7.98e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling by GPCR—HRAS—hematologic cancer	3.13e-05	0.000399	CbGpPWpGaD
Tadalafil—Asthenia—Methotrexate—hematologic cancer	3.11e-05	7.78e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CDKN1B—hematologic cancer	3.08e-05	0.000393	CbGpPWpGaD
Tadalafil—Nausea—Prednisone—hematologic cancer	3.08e-05	7.7e-05	CcSEcCtD
Tadalafil—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.06e-05	7.67e-05	CcSEcCtD
Tadalafil—Pruritus—Methotrexate—hematologic cancer	3.06e-05	7.67e-05	CcSEcCtD
Tadalafil—PDE11A—GPCR downstream signaling—AKT1—hematologic cancer	3.04e-05	0.000388	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CASP3—hematologic cancer	3.02e-05	0.000385	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL2—hematologic cancer	3.01e-05	0.000384	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—IL6—hematologic cancer	3e-05	0.000382	CbGpPWpGaD
Tadalafil—Hypersensitivity—Epirubicin—hematologic cancer	2.98e-05	7.47e-05	CcSEcCtD
Tadalafil—Urticaria—Doxorubicin—hematologic cancer	2.98e-05	7.45e-05	CcSEcCtD
Tadalafil—Abdominal pain—Doxorubicin—hematologic cancer	2.96e-05	7.42e-05	CcSEcCtD
Tadalafil—Diarrhoea—Methotrexate—hematologic cancer	2.96e-05	7.41e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CCND1—hematologic cancer	2.93e-05	0.000374	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—JUN—hematologic cancer	2.93e-05	0.000374	CbGpPWpGaD
Tadalafil—Asthenia—Epirubicin—hematologic cancer	2.91e-05	7.28e-05	CcSEcCtD
Tadalafil—Pruritus—Epirubicin—hematologic cancer	2.87e-05	7.18e-05	CcSEcCtD
Tadalafil—Dizziness—Methotrexate—hematologic cancer	2.86e-05	7.17e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CDKN1A—hematologic cancer	2.84e-05	0.000362	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PTEN—hematologic cancer	2.83e-05	0.000361	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GMPS—hematologic cancer	2.81e-05	0.000358	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PHYH—hematologic cancer	2.81e-05	0.000358	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—FTCD—hematologic cancer	2.81e-05	0.000358	CbGpPWpGaD
Tadalafil—Diarrhoea—Epirubicin—hematologic cancer	2.77e-05	6.94e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—MAPK8—hematologic cancer	2.77e-05	0.000354	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—AKT1—hematologic cancer	2.76e-05	0.000353	CbGpPWpGaD
Tadalafil—Hypersensitivity—Doxorubicin—hematologic cancer	2.76e-05	6.91e-05	CcSEcCtD
Tadalafil—Vomiting—Methotrexate—hematologic cancer	2.75e-05	6.89e-05	CcSEcCtD
Tadalafil—Rash—Methotrexate—hematologic cancer	2.73e-05	6.83e-05	CcSEcCtD
Tadalafil—Dermatitis—Methotrexate—hematologic cancer	2.73e-05	6.83e-05	CcSEcCtD
Tadalafil—Headache—Methotrexate—hematologic cancer	2.71e-05	6.79e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—EP300—hematologic cancer	2.7e-05	0.000345	CbGpPWpGaD
Tadalafil—Asthenia—Doxorubicin—hematologic cancer	2.69e-05	6.73e-05	CcSEcCtD
Tadalafil—Dizziness—Epirubicin—hematologic cancer	2.68e-05	6.71e-05	CcSEcCtD
Tadalafil—Pruritus—Doxorubicin—hematologic cancer	2.65e-05	6.64e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—SRC—hematologic cancer	2.63e-05	0.000335	CbGpPWpGaD
Tadalafil—Vomiting—Epirubicin—hematologic cancer	2.58e-05	6.45e-05	CcSEcCtD
Tadalafil—Nausea—Methotrexate—hematologic cancer	2.57e-05	6.44e-05	CcSEcCtD
Tadalafil—CYP3A4—Metabolism—SMPD3—hematologic cancer	2.57e-05	0.000328	CbGpPWpGaD
Tadalafil—Diarrhoea—Doxorubicin—hematologic cancer	2.56e-05	6.42e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—VEGFA—hematologic cancer	2.56e-05	0.000326	CbGpPWpGaD
Tadalafil—Rash—Epirubicin—hematologic cancer	2.55e-05	6.39e-05	CcSEcCtD
Tadalafil—Dermatitis—Epirubicin—hematologic cancer	2.55e-05	6.39e-05	CcSEcCtD
Tadalafil—Headache—Epirubicin—hematologic cancer	2.54e-05	6.35e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—STAT3—hematologic cancer	2.53e-05	0.000323	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—NRAS—hematologic cancer	2.53e-05	0.000322	CbGpPWpGaD
Tadalafil—Dizziness—Doxorubicin—hematologic cancer	2.48e-05	6.21e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—MAPK3—hematologic cancer	2.42e-05	0.000309	CbGpPWpGaD
Tadalafil—Nausea—Epirubicin—hematologic cancer	2.41e-05	6.02e-05	CcSEcCtD
Tadalafil—Vomiting—Doxorubicin—hematologic cancer	2.38e-05	5.97e-05	CcSEcCtD
Tadalafil—Rash—Doxorubicin—hematologic cancer	2.36e-05	5.92e-05	CcSEcCtD
Tadalafil—Dermatitis—Doxorubicin—hematologic cancer	2.36e-05	5.91e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—MYC—hematologic cancer	2.35e-05	0.0003	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TGFB1—hematologic cancer	2.35e-05	0.0003	CbGpPWpGaD
Tadalafil—Headache—Doxorubicin—hematologic cancer	2.35e-05	5.88e-05	CcSEcCtD
Tadalafil—CYP3A4—Metabolism—ASNS—hematologic cancer	2.25e-05	0.000287	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—B3GAT1—hematologic cancer	2.25e-05	0.000287	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—DCK—hematologic cancer	2.25e-05	0.000287	CbGpPWpGaD
Tadalafil—Nausea—Doxorubicin—hematologic cancer	2.23e-05	5.57e-05	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—KRAS—hematologic cancer	2.18e-05	0.000278	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HDC—hematologic cancer	2.13e-05	0.000272	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CA—hematologic cancer	2e-05	0.000255	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CDA—hematologic cancer	1.95e-05	0.000248	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TP53—hematologic cancer	1.93e-05	0.000247	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PC—hematologic cancer	1.87e-05	0.000239	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HRAS—hematologic cancer	1.85e-05	0.000236	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GBA—hematologic cancer	1.81e-05	0.000231	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.81e-05	0.000231	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL6—hematologic cancer	1.77e-05	0.000226	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTAP—hematologic cancer	1.66e-05	0.000211	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKT1—hematologic cancer	1.63e-05	0.000208	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—FHL2—hematologic cancer	1.48e-05	0.000188	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AGRN—hematologic cancer	1.45e-05	0.000185	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—IDH2—hematologic cancer	1.37e-05	0.000175	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HMMR—hematologic cancer	1.37e-05	0.000175	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.29e-05	0.000165	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CA9—hematologic cancer	1.25e-05	0.00016	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ACP5—hematologic cancer	1.25e-05	0.00016	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.24e-05	0.000158	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—IDH1—hematologic cancer	1.18e-05	0.000151	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TXN—hematologic cancer	1.17e-05	0.000149	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.17e-05	0.000149	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.17e-05	0.000149	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.14e-05	0.000146	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.1e-05	0.00014	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.07e-05	0.000136	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.07e-05	0.000136	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.04e-05	0.000133	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NUP98—hematologic cancer	1.01e-05	0.000129	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ADCY7—hematologic cancer	9.78e-06	0.000125	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOA3—hematologic cancer	9.78e-06	0.000125	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NUP214—hematologic cancer	9.71e-06	0.000124	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ABCG2—hematologic cancer	9.51e-06	0.000121	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTR—hematologic cancer	9.51e-06	0.000121	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ENO2—hematologic cancer	9.33e-06	0.000119	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTT1—hematologic cancer	9.05e-06	0.000115	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—SDC1—hematologic cancer	8.84e-06	0.000113	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NQO1—hematologic cancer	7.52e-06	9.59e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CD44—hematologic cancer	7.52e-06	9.59e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYCS—hematologic cancer	7.11e-06	9.08e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	7.07e-06	9.02e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTP1—hematologic cancer	6.27e-06	8e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ABCB1—hematologic cancer	5.94e-06	7.57e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NCOR1—hematologic cancer	5.76e-06	7.35e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTM1—hematologic cancer	5.76e-06	7.35e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTHFR—hematologic cancer	5.09e-06	6.5e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CG—hematologic cancer	4.28e-06	5.46e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.97e-06	5.06e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CD—hematologic cancer	3.76e-06	4.8e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALB—hematologic cancer	3.71e-06	4.74e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3R1—hematologic cancer	3.55e-06	4.53e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CB—hematologic cancer	3.28e-06	4.18e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PTEN—hematologic cancer	2.83e-06	3.61e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—EP300—hematologic cancer	2.7e-06	3.45e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2e-06	2.55e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AKT1—hematologic cancer	1.63e-06	2.08e-05	CbGpPWpGaD
